Filing identity and business context
The supplied filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016; it is not identified as a LifeMD, Inc. filing. Immudyne sells yeast beta-glucan immune-support ingredients and finished cosmetic products. Results include its controlled joint venture, Innate Scientific, which operated in finished cosmetics and contributed revenue in the quarter.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Net sales | $1.641 million | $288,277 |
| Cost of sales | $1.338 million | $74,216 |
| Gross profit / margin | $303,086 / 18% | $214,061 / 74% |
| Operating expenses | $408,182 | $206,227 |
| Operating income (loss) | $(105,096) | $7,834 |
| Net income (loss) | $(108,159) | $1,666 |
| Net income (loss) attributable to Immudyne | $(62,049) | $1,666 |
| Operating cash flow | $(122,155) | $(70,187) |
- Sales rose 469%, primarily due to $1.375 million of finished cosmetic product sales through Innate; management said the additives business remained broadly consistent with the prior year.
- Gross margin fell to 18% from 74%. Management attributed the decline to approximately $890,000 of upfront advertising and marketing costs supporting Innate’s sales launch.
- Cash was $203,622 at March 31, down from $232,984 at year-end. Current assets were $641,454 and current liabilities $436,963, implying working capital of about $204,000 and a current ratio of about 1.5.
- Debt included a $100,000 commercial loan at 11%, due November 1, 2016. Accounts payable and accrued expenses were $336,963.
- Operating cash use was partly offset by $92,793 of financing cash from the noncontrolling-interest investment in the subsidiary. Net cash declined $29,362 during the quarter.
- Inventory increased to $138,494 from $61,051; net receivables increased to $299,338 from $154,436. The receivables reserve was approximately $76,000 at quarter-end.
Material changes and management outlook
- The newly operating finished-cosmetics segment drove the large year-over-year increase in sales, but its launch marketing and operating costs contributed to the consolidated loss. The filing reports $517,000 of customer discounts, returns, rebates, and other adjustments for the quarter.
- Management expected upfront marketing expenses to decline as a percentage of sales as Innate matured. This is an expectation, not quantified financial guidance; the filing provides no formal revenue or earnings forecast.
- Management said operations might fund the business through 2016, but also stated that increased sales and/or additional capital would be needed to meet 2016 operating and capital requirements. Potential sources include equity, debt, or support from officers and directors; availability and timing are not assured.
- The company disclosed substantial doubt about its ability to continue as a going concern, citing its approximately $8.6 million accumulated deficit and negative operating cash flows.
- On April 1, 2016, after quarter-end, Immudyne’s ownership and voting interest in Innate increased to 78.16667%; two other members received one million restricted Immudyne shares each under service agreements.
- Disclosure controls were deemed ineffective. Reported material weaknesses included inadequate segregation of duties, insufficient accounting and SEC-reporting procedures, inadequate controls over Innate, weak computer access and disaster-recovery safeguards, and no written whistleblower policy.
- Other risks include dependence on a concentrated customer (one customer represented 16% of sales and 54% of receivables at March 31), potential dilution or increased debt costs, product regulation, intellectual-property protection, and the Kentucky facility lease expiring May 31, 2016.
- Management reported no known legal proceedings expected to have a material adverse effect and no material off-balance-sheet arrangements.
Key facts for investors to verify
- Confirm the intended issuer: the provided filing names Immudyne, Inc., not LifeMD, Inc.
- Review the sustainability and unit economics of Innate’s sales, including whether launch marketing spend falls and margins improve as management expected.
- Assess cash runway, the November 2016 loan maturity, and whether additional financing or increased sales are required.
- Examine customer concentration, receivables collectability, reserve adequacy, and the unusually large reported customer discounts and rebates.
- Review the post-quarter ownership change, share issuance, and resulting control and dilution implications.
- Track remediation of the disclosed material weaknesses and confirm the facility lease arrangement after its stated expiration.